Andrew Lipsky

1.8k total citations
23 papers, 694 citations indexed

About

Andrew Lipsky is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Andrew Lipsky has authored 23 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 7 papers in Hematology. Recurrent topics in Andrew Lipsky's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Andrew Lipsky is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Andrew Lipsky collaborates with scholars based in United States, Malaysia and Denmark. Andrew Lipsky's co-authors include Nicole Lamanna, Adrian Wiestner, Gerald E. Marti, Yair Herishanu, Ben‐Zion Katz, Janet Valdez, Xin Tian, Sarah E. M. Herman, Georg Aue and Clare Sun and has published in prestigious journals such as Blood, Neurology and Cancer.

In The Last Decade

Andrew Lipsky

20 papers receiving 687 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Lipsky United States 8 566 403 260 203 109 23 694
Małgorzata Wach Poland 11 573 1.0× 448 1.1× 199 0.8× 221 1.1× 102 0.9× 35 695
Saad M. B. Rassam United Kingdom 8 495 0.9× 456 1.1× 285 1.1× 142 0.7× 65 0.6× 15 686
Indu Lal United States 6 518 0.9× 338 0.8× 290 1.1× 372 1.8× 79 0.7× 14 787
Dimitra Anagnostou Greece 16 251 0.4× 303 0.8× 132 0.5× 188 0.9× 110 1.0× 41 700
Anna Vardi Greece 14 349 0.6× 228 0.6× 323 1.2× 128 0.6× 69 0.6× 52 578
Gerhard Postner Austria 7 354 0.6× 324 0.8× 127 0.5× 109 0.5× 81 0.7× 8 613
Archrob Khuhapinant Thailand 11 261 0.5× 201 0.5× 118 0.5× 209 1.0× 56 0.5× 37 550
Andres Quesada United States 15 206 0.4× 230 0.6× 93 0.4× 234 1.2× 125 1.1× 59 639
Niels Smedegaard Andersen Denmark 13 313 0.6× 499 1.2× 243 0.9× 222 1.1× 82 0.8× 38 834
Anastasia Athanasiadou Greece 16 314 0.6× 185 0.5× 205 0.8× 203 1.0× 141 1.3× 45 604

Countries citing papers authored by Andrew Lipsky

Since Specialization
Citations

This map shows the geographic impact of Andrew Lipsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Lipsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Lipsky more than expected).

Fields of papers citing papers by Andrew Lipsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Lipsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Lipsky. The network helps show where Andrew Lipsky may publish in the future.

Co-authorship network of co-authors of Andrew Lipsky

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Lipsky. A scholar is included among the top collaborators of Andrew Lipsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Lipsky. Andrew Lipsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lipsky, Andrew, et al.. (2025). ABCL-1435: Expanding Frontline Therapy: BV-AVD in the Understudied HIV-Positive Classical Hodgkin’s Lymphoma Population. Clinical Lymphoma Myeloma & Leukemia. 25. S801–S801.
2.
Axsom, Kelly, J. Fried, F. Latif, et al.. (2025). Case Report: A Unique Case of Hemophagocytic Lymphohistiocytosis in Heart Transplant. Transplantation Proceedings. 57(3). 481–484.
3.
Lipsky, Andrew, et al.. (2024). Safety of CAR T-Cell Therapy in Patients with Active Autoimmune Diseases: A Case Report (P3-14.003). Neurology. 102(17_supplement_1).
4.
Soumerai, Jacob D., Jacqueline C. Barrientos, Inhye E. Ahn, et al.. (2024). Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL. Blood Advances. 9(5). 1213–1229. 5 indexed citations
5.
Lipsky, Andrew, et al.. (2023). Measurable Residual Disease Monitoring in Lymphoma. Current Hematologic Malignancy Reports. 18(6). 292–304. 1 indexed citations
6.
Ryu, Yun Kyoung, et al.. (2022). Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. Journal of Clinical Medicine. 11(16). 4928–4928. 7 indexed citations
7.
Jin, Zhezhen, et al.. (2022). Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder. Blood. 140(Supplement 1). 3794–3795. 3 indexed citations
8.
Jin, Zhezhen, et al.. (2022). Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder. Blood. 140(Supplement 1). 3777–3778. 1 indexed citations
9.
Lipsky, Andrew & Nicole Lamanna. (2022). Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia. Cancer. 129(1). 18–31. 6 indexed citations
10.
Lipsky, Andrew, Brian T. Hill, Allison Winter, et al.. (2021). High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 138(Supplement 1). 1555–1555. 2 indexed citations
11.
Lipsky, Andrew & Nicole Lamanna. (2020). Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology. 2020(1). 336–345. 103 indexed citations
12.
Lipsky, Andrew & Peter Martin. (2016). Bendamustine–rituximab in mantle cell lymphoma. The Lancet Haematology. 4(1). e2–e3. 8 indexed citations
13.
Lipsky, Andrew, Mohammed Z.H. Farooqui, Xin Tian, et al.. (2015). Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 100(12). 1571–1578. 131 indexed citations
14.
Marchalik, Daniel, et al.. (2015). Risk Factors for Catheter Associated Urinary Tract Infections in a Pediatric Institution. The Journal of Urology. 195(4 Part 2). 1306–1311. 16 indexed citations
15.
Sun, Clare, Xin Tian, Yuh Shan Lee, et al.. (2015). Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 126(19). 2213–2219. 166 indexed citations
16.
Herman, Sarah E. M., Carsten Utoft Niemann, Mahfooz Farooqui, et al.. (2014). Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 28(11). 2188–2196. 131 indexed citations
17.
Saba, Nakhle S., et al.. (2013). Cancer of the Indiana Pouch: A Case Report and Review of the Literature. Clinical Genitourinary Cancer. 11(4). e30–e34. 2 indexed citations
18.
Herishanu, Yair, Ben‐Zion Katz, Andrew Lipsky, & Adrian Wiestner. (2013). Biology of Chronic Lymphocytic Leukemia in Different Microenvironments. Hematology/Oncology Clinics of North America. 27(2). 173–206. 78 indexed citations
19.
Marchalik, Daniel, Andrew Lipsky, Dmitriy Petrov, Jeff D. Harvell, & Sandy Milgraum. (2012). Dermatologic Presentations of Orthopedic Pathologies. American Journal of Clinical Dermatology. 13(5). 293–310. 13 indexed citations
20.
Farooqui, Mohammed, Georg Aue, Janet Valdez, et al.. (2012). Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death.. Blood. 120(21). 2899–2899. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Małgorzata Wach Breakdown of academic impact, for papers by Saad M. B. Rassam Breakdown of academic impact, for papers by Indu Lal Breakdown of academic impact, for papers by Dimitra Anagnostou Breakdown of academic impact, for papers by Anna Vardi Breakdown of academic impact, for papers by Gerhard Postner Breakdown of academic impact, for papers by Archrob Khuhapinant Breakdown of academic impact, for papers by Andres Quesada Breakdown of academic impact, for papers by Niels Smedegaard Andersen Breakdown of academic impact, for papers by Anastasia Athanasiadou
Rankless by CCL
2026